Impact of Electroconvulsive Therapy on Brain Networks and Sleep
Disruptions of Brain Networks and Sleep by Electroconvulsive Therapy
This study is testing how electroconvulsive therapy (ECT) affects sleep and brain activity in people with treatment-resistant depression to see if it helps improve their condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 21 Years to 65 Years |
| Sex | All |
| Sponsor | Washington University School of Medicine Academic / other |
| Locations | 1 site (St Louis, Missouri) |
| Trial ID | NCT05905705 on ClinicalTrials.gov |
What this trial studies
This study evaluates how electroconvulsive therapy (ECT) affects sleep-wake regulation and the efficiency of information transfer in brain networks among patients with treatment-resistant depression. Using electroencephalography (EEG), researchers will analyze functional networks and measure local and global information transfer during different states of arousal. The study aims to assess the relationship between sleep slow-wave activity and awake local efficiency, as well as the correlation between depression severity and awake local efficiency throughout the course of ECT.
Who should consider this trial
Good fit: Ideal candidates are individuals diagnosed with treatment-resistant depression who have not responded to at least two antidepressant medications.
Not a fit: Patients with schizophrenia or schizoaffective disorders will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of how ECT improves sleep and brain function in patients with treatment-resistant depression.
How similar studies have performed: While studies on ECT have been conducted, this specific approach using EEG to analyze brain networks and sleep is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Referral for initial ECT index course for Treatment-Resistant Depression (TRD), unipolar major depressive disorder or bipolar depression. Historic failure of response or remission to at least two antidepressant medications of sufficient dose and duration will be used for TRD diagnostic. Exclusion Criteria: * Diagnoses of schizophrenia or schizoaffective disorders. * Subjects who are unable to tolerate the Dreem device for sleep recordings will be excluded from the study.
Where this trial is running
St Louis, Missouri
- Washington University School of Medicine/Barnes-Jewish Hospital — St Louis, Missouri, United States (Recruiting)
Study contacts
- Principal investigator: MohammadMehdi Kafashan — Washington University School of Medicine in St. Louis
- Study coordinator: Robby Greenspan
- Email: greenspan@wustl.edu
- Phone: 314-273-6129
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.